| Dr Mark D Borchelt, MD, FACE | |
|
4540 W Railroad St, Gulfport, MS 39501-2480 | |
| (228) 867-6062 | |
| (228) 867-2598 |
| Full Name | Dr Mark D Borchelt |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 41 Years |
| Location | 4540 W Railroad St, Gulfport, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194776286 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
| Singing River Health System | Pascagoula, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hospital At Gulfport | 2466524012 | 376 |
News Archive
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
TyraTech, Inc., a life sciences technology company focused on nature-derived insect and parasite control products, announces a number of new initiatives including its expansion into the European market; the launch of a new product to complement the Vamousse range: Vamousse Lice Elimination for home cleaning; and further expansion of its distribution network in both the US and the UK.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE by Siddhivinayak Hirve from the World Health Organization, Geneva, Switzerland, and colleagues.
› Verified 7 days ago
| Entity Name | Memorial Hospital At Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215546635 PECOS PAC ID: 2466524012 Enrollment ID: O20090515000396 |
News Archive
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
TyraTech, Inc., a life sciences technology company focused on nature-derived insect and parasite control products, announces a number of new initiatives including its expansion into the European market; the launch of a new product to complement the Vamousse range: Vamousse Lice Elimination for home cleaning; and further expansion of its distribution network in both the US and the UK.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE by Siddhivinayak Hirve from the World Health Organization, Geneva, Switzerland, and colleagues.
› Verified 7 days ago
| Entity Name | The National Diabetes & Obesity Research Institute At Tradition, Missi |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003397530 PECOS PAC ID: 6103170006 Enrollment ID: O20181113000364 |
News Archive
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
TyraTech, Inc., a life sciences technology company focused on nature-derived insect and parasite control products, announces a number of new initiatives including its expansion into the European market; the launch of a new product to complement the Vamousse range: Vamousse Lice Elimination for home cleaning; and further expansion of its distribution network in both the US and the UK.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE by Siddhivinayak Hirve from the World Health Organization, Geneva, Switzerland, and colleagues.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark D Borchelt, MD, FACE Po Box 1810, Gulfport, MS 39502-1810 Ph: (228) 867-6062 | Dr Mark D Borchelt, MD, FACE 4540 W Railroad St, Gulfport, MS 39501-2480 Ph: (228) 867-6062 |
News Archive
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
TyraTech, Inc., a life sciences technology company focused on nature-derived insect and parasite control products, announces a number of new initiatives including its expansion into the European market; the launch of a new product to complement the Vamousse range: Vamousse Lice Elimination for home cleaning; and further expansion of its distribution network in both the US and the UK.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE by Siddhivinayak Hirve from the World Health Organization, Geneva, Switzerland, and colleagues.
› Verified 7 days ago
Dr. Nabil Azar, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1340 Broad Ave, Suite 310, Gulfport, MS 39501 Phone: 228-575-1400 Fax: 228-575-1414 | |
Dr. Fahad Javed, M.D., Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4215 15th St, Gulfport, MS 39501 Phone: 228-863-5211 Fax: 228-863-4101 | |
Indrajit J Patel, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-867-5201 Fax: 228-867-3152 | |
James K. Campbell, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 15190 Community Rd Ste 240, Gulfport, MS 39503 Phone: 228-575-7104 Fax: 228-539-6766 | |
Dr. Thomas Blanks, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1110 Broad Ave, Suite 700, Gulfport, MS 39501 Phone: 228-864-0314 Fax: 228-864-0425 | |
Dr. Stephanie Fussell, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1340 Broad Ave Ste 330, Gulfport, MS 39501 Phone: 228-575-1234 Fax: 228-867-4828 | |
Dr. Malcolm Scott Dean, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-867-5201 Fax: 228-867-3152 |